[31] [32] Patients experiencing recurrent yeast infections despite preventive measures should be referred for comprehensive evaluation, particularly if they have poorly controlled diabetes, are immunosuppressed, are pregnant, or have had multiple treatment failures
Globally, the GLP-1 receptor agonist market is valued at USD 62.86 billion in 2025, projected to surge at a 17.5% compound annual growth rate (CAGR) through 2034, driven by expanding indications for obesity, cardiovascular benefits, and even potential neuroprotective effects
Six studies have evaluated the effects of the mimetics, exenatide (86, 108, 109, 134) or liraglutide (79, 109)
It activates various downstream pathways of nuclear genes by binding to a variety of membrane-bound receptors present on the postsynaptic membrane, which regulate secondary messenger systems